Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

IKK/NF-κB signaling contributes to glioblastoma stem cell maintenance.

Rinkenbaugh AL, Cogswell PC, Calamini B, Dunn DE, Persson AI, Weiss WA, Lo DC, Baldwin AS.

Oncotarget. 2016 Oct 25;7(43):69173-69187. doi: 10.18632/oncotarget.12507.

2.

The NF-κB Pathway and Cancer Stem Cells.

Rinkenbaugh AL, Baldwin AS.

Cells. 2016 Apr 6;5(2). pii: E16. doi: 10.3390/cells5020016. Review.

3.

Therapeutically engineered induced neural stem cells are tumour-homing and inhibit progression of glioblastoma.

Bagó JR, Alfonso-Pecchio A, Okolie O, Dumitru R, Rinkenbaugh A, Baldwin AS, Miller CR, Magness ST, Hingtgen SD.

Nat Commun. 2016 Feb 2;7:10593. doi: 10.1038/ncomms10593.

4.

Oncogenic EGFR signaling activates an mTORC2-NF-κB pathway that promotes chemotherapy resistance.

Tanaka K, Babic I, Nathanson D, Akhavan D, Guo D, Gini B, Dang J, Zhu S, Yang H, De Jesus J, Amzajerdi AN, Zhang Y, Dibble CC, Dan H, Rinkenbaugh A, Yong WH, Vinters HV, Gera JF, Cavenee WK, Cloughesy TF, Manning BD, Baldwin AS, Mischel PS.

Cancer Discov. 2011 Nov;1(6):524-38. doi: 10.1158/2159-8290.CD-11-0124. Epub 2011 Sep 13.

5.

Monoallelic deletion of NFKBIA in glioblastoma: when less is more.

Rinkenbaugh AL, Baldwin AS.

Cancer Cell. 2011 Feb 15;19(2):163-5. doi: 10.1016/j.ccr.2011.01.045.

Supplemental Content

Loading ...
Support Center